Health systems need a
unified voice.
Cell, gene and advanced therapies are rapidly changing healthcare. While numerous organizations support scientists, clinicians, researchers, and pharmaceutical manufacturers, there has been no dedicated organization focused on the unique needs of health systems tasked with delivering these therapies. That gap inspired the creation of the Advanced Therapies Consortium (ATC). ATC provides a trusted community to navigate the complexities of cell, gene and advanced therapy delivery and shape the policies and practices that affect patient care, program economics, and long-term sustainability.
Our members recognize that success requires more than clinical excellence. Sustainable cell, gene and advanced therapy programs demand coordinated approaches to operations, reimbursement, workforce development, patient access, regulatory compliance, and long-term program growth.
Why TATC Exists
Health systems need a unified voice.
Cell, gene and advanced therapies are rapidly changing healthcare. While numerous organizations support scientists, clinicians, researchers, and pharmaceutical manufacturers, there has been no dedicated organization focused on the unique needs of health systems tasked with delivering these therapies. That gap inspired the creation of The Advanced Therapies Consortium (ATC). ATC provides a trusted community to navigate the complexities of cell, gene and advanced therapy delivery and shape the policies and practices that affect patient care, program economics, and long-term sustainability.
Our members recognize that success requires more than clinical excellence. Sustainable cell, gene and advanced therapy programs demand coordinated approaches to operations, reimbursement, workforce development, patient access, regulatory compliance, and long-term program growth.
Our Vision
Our Vision is to create a future where every health system is equipped to deliver cell, gene and advanced therapies effectively, sustainably, and at scale.
Our Community
- Health systems, hospitals, and provider networks
- Executive and C-suite leadership
- Academic medical centers
- Cell, gene and advanced therapy program administrators
- Clinical operations teams
- Financial and reimbursement leaders
- Supply chain and logistics professionals
- Industry and strategic partners
Focus Areas
- Program Readiness & Operations: Support organizations as they build, launch, and optimize cell, gene and advanced therapy services.
- Policy & Advocacy: Advance policies that promote patient access and strengthen health system sustainability.
- Economics & Reimbursement: Address the financial realities of delivering advanced therapies and develop practical solutions.
- Workforce Development: Prepare clinical and operational teams for the evolving demands of advanced therapy care.
- Knowledge Sharing: Create opportunities for collaboration, benchmarking, and peer-to-peer learning.
Our Commitment
ATC is committed to helping health systems move beyond readiness and toward leadership in the rapidly evolving cell, gene and advanced therapies landscape.